Expand NRSN Menu
NRSN MENU

NRSN Latest Press Releases

-- April 6, 2026 --

NeuroSense Granted Brazilian Patent Covering PrimeC Composition PRNewswire 9:20 AM

-- April 3, 2026 --

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements PRNewswire 10:03 AM

-- March 31, 2026 --

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PRNewswire 9:20 AM

-- March 24, 2026 --

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout PRNewswire 9:01 AM

-- March 18, 2026 --

/C O R R E C T I O N -- NeuroSense/ PRNewswire 10:45 AM
PrimeC New Data to Be Presented at AD/PD 2026 Conference PRNewswire 8:00 AM

-- March 16, 2026 --

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity PRNewswire 11:34 AM

-- March 9, 2026 --

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PRNewswire 11:08 AM

-- February 18, 2026 --

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PRNewswire 9:05 AM

-- February 9, 2026 --

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition PRNewswire 9:20 AM

-- January 21, 2026 --

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PRNewswire 8:30 AM

-- January 8, 2026 --

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PRNewswire 8:45 AM

-- December 4, 2025 --

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PRNewswire 7:30 AM

-- November 24, 2025 --

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS PRNewswire 9:56 AM
Market Data Delayed 15 Minutes